• Je něco špatně v tomto záznamu ?

Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease

T. Kucharzik, R. Wilkens, MA. D'Agostino, G. Maconi, M. Le Bars, M. Lahaye, I. Bravatà, M. Nazar, L. Ni, E. Ercole, M. Allocca, N. Machková, FAE. de Voogd, C. Palmela, R. Vaughan, C. Maaser, STARDUST Intestinal Ultrasound study group

. 2023 ; 21 (1) : 153-163.e12. [pub] 20220714

Jazyk angličtina Země Spojené státy americké

Typ dokumentu multicentrická studie, klinické zkoušky, fáze III, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032085

BACKGROUND & AIMS: In this STARDUST substudy, the effect of ustekinumab on transmural bowel inflammation was assessed in adults with moderate-to-severe Crohn's disease (CD) by using intestinal ultrasound (IUS), a noninvasive imaging procedure. METHODS: STARDUST was an international, multicenter, phase 3b, interventional, randomized controlled trial specifically designed to compare treat-to-target and standard-of-care treatment strategies in ustekinumab-treated CD patients. In this substudy, the most affected bowel segment at baseline by IUS was used for all analyses. Key IUS endpoints (centrally read, parameter-blinded) were IUS response, transmural remission, bowel wall thickness (BWT), blood flow, bowel wall stratification, and inflammatory fat. RESULTS: Seventy-seven patients were evaluated. IUS response could be determined 4 weeks after treatment initiation, with progressive improvement through week 48. IUS response and transmural remission rates at week 48 were 46.3% and 24.1%, respectively. IUS response, transmural remission, BWT, and blood flow normalization rates were more pronounced in the colon and biologic-naive patients. Fair/moderate reliability (κ = 0.21-0.51) was observed between week 4 IUS response and week 48 overall endoscopic response and fecal calprotectin/complete biomarker outcomes. Endoscopy and IUS baseline agreement was >90% in determining the terminal ileum as the most affected bowel segment. IUS response absence at week 4 was associated with no endoscopic response (based on the simplified endoscopic score for Crohn's disease terminal ileum subscore) at week 48 (negative predictive value = 73%). CONCLUSIONS: In this first international, multicenter, interventional study, IUS showed that ustekinumab-treated CD patients achieved progressive IUS response (46.3%) and transmural remission (24.1%) through week 48, with a more robust response in the colon and biologic-naive patients. CLINICALTRIALS: gov number: NCT03107793.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032085
003      
CZ-PrNML
005      
20230131151233.0
007      
ta
008      
230120s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.cgh.2022.05.055 $2 doi
035    __
$a (PubMed)35842121
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kucharzik, Torsten $u Klinik für Allgemeine Innere Medizin und Gastroenterologie, Klinikum Lüneburg, Lüneburg, Germany. Electronic address: Torsten.Kucharzik@klinikum-lueneburg.de
245    10
$a Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease / $c T. Kucharzik, R. Wilkens, MA. D'Agostino, G. Maconi, M. Le Bars, M. Lahaye, I. Bravatà, M. Nazar, L. Ni, E. Ercole, M. Allocca, N. Machková, FAE. de Voogd, C. Palmela, R. Vaughan, C. Maaser, STARDUST Intestinal Ultrasound study group
520    9_
$a BACKGROUND & AIMS: In this STARDUST substudy, the effect of ustekinumab on transmural bowel inflammation was assessed in adults with moderate-to-severe Crohn's disease (CD) by using intestinal ultrasound (IUS), a noninvasive imaging procedure. METHODS: STARDUST was an international, multicenter, phase 3b, interventional, randomized controlled trial specifically designed to compare treat-to-target and standard-of-care treatment strategies in ustekinumab-treated CD patients. In this substudy, the most affected bowel segment at baseline by IUS was used for all analyses. Key IUS endpoints (centrally read, parameter-blinded) were IUS response, transmural remission, bowel wall thickness (BWT), blood flow, bowel wall stratification, and inflammatory fat. RESULTS: Seventy-seven patients were evaluated. IUS response could be determined 4 weeks after treatment initiation, with progressive improvement through week 48. IUS response and transmural remission rates at week 48 were 46.3% and 24.1%, respectively. IUS response, transmural remission, BWT, and blood flow normalization rates were more pronounced in the colon and biologic-naive patients. Fair/moderate reliability (κ = 0.21-0.51) was observed between week 4 IUS response and week 48 overall endoscopic response and fecal calprotectin/complete biomarker outcomes. Endoscopy and IUS baseline agreement was >90% in determining the terminal ileum as the most affected bowel segment. IUS response absence at week 4 was associated with no endoscopic response (based on the simplified endoscopic score for Crohn's disease terminal ileum subscore) at week 48 (negative predictive value = 73%). CONCLUSIONS: In this first international, multicenter, interventional study, IUS showed that ustekinumab-treated CD patients achieved progressive IUS response (46.3%) and transmural remission (24.1%) through week 48, with a more robust response in the colon and biologic-naive patients. CLINICALTRIALS: gov number: NCT03107793.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a Crohnova nemoc $x diagnostické zobrazování $x farmakoterapie $7 D003424
650    _2
$a ustekinumab $x terapeutické užití $7 D000069549
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a kolon $7 D003106
650    _2
$a indukce remise $7 D012074
650    12
$a biologické přípravky $7 D001688
650    _2
$a výsledek terapie $7 D016896
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wilkens, Rune $u Digestive Disease Center, Bispebjerg Hospital Copenhagen, Denmark; Gastro Unit, Section of Medicine, Hvidovre Hospital Copenhagen, Denmark
700    1_
$a D'Agostino, Maria-Antonietta $u Università Cattolica del Sacro Cuore, UOC Reumatologia, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Roma, Italy
700    1_
$a Maconi, Giovanni $u Gastroenterology Unit, Department of Biomedical and Clinical Sciences; "Luigi Sacco" University Hospital, University of Milan, Milan, Italy
700    1_
$a Le Bars, Manuela $u Janssen-Cilag SARL, Issy-les-Moulineaux, France
700    1_
$a Lahaye, Marjolein $u Janssen-Cilag B.V., Breda, The Netherlands
700    1_
$a Bravatà, Ivana $u Janssen-Cilag S.p.A., Milan, Italy
700    1_
$a Nazar, Maciej $u Janssen-Cilag Polska Sp. Z. o.o, Warsaw, Poland
700    1_
$a Ni, Lioudmila $u Janssen-Cilag Russia, Moscow, Russian Federation
700    1_
$a Ercole, Elena $u Gastroenterology Unit, Mauriziano Hospital, Turin, Italy
700    1_
$a Allocca, Mariangela $u IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
700    1_
$a Machková, Naděžda $u Clinical and Research Center for Inflammatory Bowel Diseases, Clinical Center ISCARE, Prague, Czech Republic
700    1_
$a de Voogd, Floris A E $u Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands
700    1_
$a Palmela, Carolina $u Division of Gastroenterology, Surgical Department, Hospital Beatriz Ângelo, Loures, Portugal
700    1_
$a Vaughan, Rose $u The Royal Melbourne Hospital, Melbourne, Australia
700    1_
$a Maaser, Christian $u Ambulanzzentrum Gastroenterologie am Klinikum Lüneburg, Lüneburg, Germany
710    2_
$a STARDUST Intestinal Ultrasound study group
773    0_
$w MED00182421 $t Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association $x 1542-7714 $g Roč. 21, č. 1 (2023), s. 153-163.e12
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35842121 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151228 $b ABA008
999    __
$a ok $b bmc $g 1891081 $s 1183420
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 21 $c 1 $d 153-163.e12 $e 20220714 $i 1542-7714 $m Clinical gastroenterology and hepatology $n Clin Gastroenterol Hepatol $x MED00182421
LZP    __
$a Pubmed-20230120
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace